Drug intelligence / Profile preview

EcNΔnlpIIHCG

Development stage: Preclinical
Lead developer: Southern Medical University
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

EcNΔnlpIIHCG is an engineered live bacterial therapeutic and diagnostic agent based on the *Escherichia coli* Nissle 1917 (EcN) strain. It is specifically modified with a deletion of the *nlpI* gene to enhance the biogenesis and secretion of outer membrane vesicles (OMVs). The bacterium is engineered to express a bifunctional surface display system: the ice nucleation protein (INP) fused to histone-like protein A (HlpA) for selective targeting of tumor-associated DNA and heparan sulfate, and Cytolysin A (ClyA) fused to enhanced green fluorescent protein (EGFP) for tracking and visualization. Following oral administration, EcNΔnlpIIHCG selectively colonizes the tumor microenvironment (TME), where it serves as a fluorescent tracking tool to monitor bacterial distribution and OMV-mediated delivery. It is primarily utilized as the imaging and tracking counterpart to the therapeutic strain EcNΔnlpIIHCL (ENHL), which carries lactate oxidase to neutralize acidic stress in colorectal cancer and other solid tumors.

Targets

HS (Heparan sulfate)DNA

Beyond the preview

Go deeper on EcNΔnlpIIHCG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EcNΔnlpIIHCG.

Explore the full profile